自体外周血造血干细胞移植后序贯CIK细胞治疗急性髓系白血病

背景：细胞因子诱导的杀伤细胞作为一种有效的过继免疫治疗方法，成为治疗急性髓系白血病的一种新的手段，目前关于急性髓系白血病自体移植后序贯细胞因子诱导的杀伤细胞治疗的报道尚少，值得进一步研究。 目的：观察急性髓系白血病M2患者自体外周血造血干细胞移植后序贯细胞因子诱导的杀伤细胞治疗的临床疗效和不良反应。 方法：入选45例低、中危急性髓系白血病M2患者，其中19例在自体外周血造血干细胞移植后序贯了细胞因子诱导的杀伤细胞治疗，另26例未序贯细胞因子诱导的杀伤细胞治疗，比较两组患者的复发率、无病生存率、总生存率，观察细胞因子诱导的杀伤细胞治疗的安全性。 结果与结论：①序贯细胞因子诱导的杀伤细胞治疗组的复发率低于未序贯细胞因子诱导的杀伤细胞治疗组(21.05%，38.46%，P < 0.05)；序贯细胞因子诱导的杀伤细胞治疗组患者的2年无病生存率和2年总生存率均高于未序贯细胞因子诱导的杀伤细胞治疗组，差异均有显著性意义(P < 0.05)。②19例接受细胞因子诱导的杀伤细胞治疗的患者均顺利完成治疗方案，治疗过程中除4例出现寒战、发热外，无其他不良反应。结果显示低、中危急性髓系白血病M2患者自体外周血造血干细胞移植后序贯细胞因子诱导的杀伤细胞治疗可降低原发病的复发率，提高患者的无病生存率及总生存率，且无明显不良反应，是一种安全、有效、可行的治疗方法。中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程全文链接：

Sequential cytokine induced killer cells therapy for acute myeloid leukemia after autologous peripheral blood stem cell transplantation

BACKGROUND:Cytokine induced killer cells therapy as an effective means of adoptive immunotherapy, becomes a new way to treat acute myeloid leukemia. But, the researches about sequential cytokine induced killer cells therapy after autologous peripheral blood stem cell transplantation in acute myeloid leukemia patients are still less, which deserve further research. OBJECTIVE: Toobserve the clinical efficiency and safety of sequential cytokine induced killer cells therapy after autologous peripheral blood stem cell transplantation in acute myeloid leukemia M2 patients. METHODS:Totally 45 patients with low- or intermediate-risk acute myeloid leukemia M2 were recruited in this study. Among them, 19 patients received sequential cytokine induced killer cells therapy after autologous peripheral blood stem cell transplantation and 26 patients only received autologous peripheral blood stem cell transplantation. The relapse rate, disease-free survival, and overall survival were compared between two groups, and safety of cytokine induced killer cells therapy was observed. RESULTS AND CONCLUSION: (1) Compared with the patients only receiving autologous peripheral blood stem cell transplantation, the relapse rate was lower (21.05% vs. 38.46%; P < 0.05), and elevated percentages of the disease-free survival and overall survival were observed in the patients receiving sequential cytokine induced killer cells therapy after autologous peripheral blood stem cell transplantation (P < 0.05). (2) The 19 patients who received sequential cytokine induced killer cells therapy after autologous peripheral blood stem cell transplantation all completed the treatment scheme successfully. Only four patients appeared to have chills and fever, and no more side effects were observed. These findings suggested that the sequential cytokine induced killer cells therapy after autologous peripheral blood stem cell transplantation can improve the disease-free survival and overall survival of low- or intermediate-risk acute myeloid leukemia M2 patients without remarkable side effects, which is a safe, effective and feasible way for the treatment of acute myeloid leukemia M2.